| 2024-11-11 |
How Antibodies are Used in Cancer Immunotherapy |
| 2024-11-01 |
Engineering CDR Loops for High-Affinity Therapeutic Antibodies |
| 2024-10-28 |
The Role of Somatic Hypermutation in Developing Therapeutic Antibodies |
| 2024-10-23 |
Understanding Fully Human and Humanized Monoclonal Antibodies |
| 2024-10-20 |
Diverse and High-Affinity Antibodies: The Science Behind AbDrop™ |
| 2024-10-16 |
What is Antibody Pharmacokinetics? |
| 2024-10-10 |
How AbDrop™ and HUGO-Ab™ Cuts Antibody Discovery Time to Just 3 Months |
| 2024-10-09 |
How Chimeric Antibodies Paved the Way for Antibody Engineering Advances |
| 2024-09-25 |
The Importance of Heavy and Light Chain Pairing in Antibody Discovery |
| 2024-09-23 |
What is a VHH Library? |
| 2024-09-16 |
What is Antibody Engineering? |
| 2024-09-11 |
What are Bispecific Antibodies? |
| 2024-09-06 |
Antibody Effector Functions |
| 2024-08-29 |
Antibody Basics: Part 12 - Antibody Formats - Multispecific Antibodies |
| 2024-08-26 |
Understanding the Difference Between ADC Biosimilars and ADC Isotypes |
| 2024-08-20 |
Week 3, August 2024: VHH Antibodies Everywhere |
| 2024-07-26 |
Antibody-Mediated Phagocytosis Against Cancer |
| 2024-07-22 |
Structure and Dynamics in Antibody Therapeutics Design |
| 2024-07-19 |
Therapeutic Antibodies in Medicine: An Overview |
| 2024-07-01 |
The Unique Origin of VHH Antibodies: Camelids |
| 2024-06-14 |
Multi-Payload Antibody–Drug Conjugates |
| 2024-06-11 |
Week 2, June 2024: Ophthalmology in Focus |
| 2024-06-07 |
What Are Antibody Mimetics? |
| 2024-06-05 |
The Promise of VHH Antibodies |
| 2024-05-31 |
Antibody-Antibiotic Conjugates (AACs) in the Fight Against Bacterial Infections |
| 2024-05-29 |
The Role and Development of TCR-like Antibodies in Cancer Immunotherapy |
| 2024-05-18 |
PEGS 2024 – Boston: Highlights and Event Recap |
| 2024-05-14 |
The Emergence and Evolution of scFvs |
| 2024-05-08 |
Engineered Antibody Formats: A Historical Perspective |
| 2024-05-04 |
A Historical Overview of VHH Antibodies |
